Peter Bouwman

6.9k citations

42 papers · 3.4k indexed · 2 hit papers · h-index 22

Molecular Biology top 2%
Oncology top 2%
Genetics top 5%
Immunology top 10%
Cancer Research top 5%

Co-authors: Jos Jonkers Sjaak Philipsen Christine L. Mummery Sven Rottenberg Jean‐Philippe Pradère Catelijne Stortelers Paula Ruurs Marga A. van Rooijen
Topics: DNA Repair Mechanisms (15 papers)BRCA gene mutations in cancer (11 papers)CRISPR and Genetic Engineering (10 papers)
Cited by: Oncology Molecular Biology Cancer Research
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Nature Communications
Partner nations: Netherlands United Kingdom United States

In The Last Decade

Peter Bouwman

40 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

2012 498 citations Peter Bouwman, Jos Jonkers profile →
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

2019 476 citations Peter Bouwman, Jos Jonkers et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Peter Bouwman

Since Specialization

Citations

This map shows the geographic impact of Peter Bouwman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Bouwman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Bouwman more than expected).

Fields of papers citing papers by Peter Bouwman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Bouwman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Bouwman. The network helps show where Peter Bouwman may publish in the future.

Co-authorship network of co-authors of Peter Bouwman

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Bouwman. A scholar is included among the top collaborators of Peter Bouwman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Bouwman. Peter Bouwman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mathematical modelling reveals compound-specific stress pathway activity 2025 ·Toxicology ·(unknown),(unknown),Raju Prasad Sharma,(unknown),(unknown),(unknown),Philipp Ternes,(unknown),Marcel Leist,Peter Bouwman,Franziska Maria Zickgraf,Stefan Schildknecht,(unknown),Joost B. Beltman	1
2	A broad kinase inhibitor library live cell imaging screen using liver, kidney and cardiac hiPSC-ICAM1-eGFP reporter lineages identifies liabilities for TNFα pathway modulation 2025 ·Archives of Toxicology ·(unknown),(unknown),Janet Piñero,(unknown),Gerhard F. Ecker,(unknown),Béla Z. Schmidt,Catherine M. Verfaillie,Konstantinos Tassis,(unknown),Peter Bouwman,(unknown)	0
3	Mapping Interindividual Variability of Toxicodynamics Using High-Throughput Transcriptomics and Primary Human Hepatocytes from Fifty Donors 2024 ·Environmental Health Perspectives ·Marije Niemeijer,Witold Więcek,Shuai Fu,(unknown),Peter Bouwman,Audrey Baze,C. Parmentier,Lysiane Richert,Richard S. Paules,Frédéric Y. Bois,Bob van de Water	10
4	Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors 2023 ·Breast Cancer Research ·(unknown),(unknown),(unknown),(unknown),Hendrik J. Kuiken,Cor Lieftink,(unknown),Gerhard F. Ecker,Roderick L. Beijersbergen,Peter Bouwman,Sylvia E. Le Dévédec,Bob van de Water	9
5	Fluorescent tagging of endogenous Heme oxygenase-1 in human induced pluripotent stem cells for high content imaging of oxidative stress in various differentiated lineages 2021 ·Archives of Toxicology ·Kirsten E Snijders,(unknown),Zsuzsanna Táncos,István Bock,Annamária Téglási,(unknown),Marije Niemeijer,Peter Bouwman,Sylvia E. Le Dévédec,Martijn J. Moné,(unknown),Manoj Kumar,Anja Wilmes,Paul Jennings,Catherine M. Verfaillie,Julianna Kobolák,Bas ter Braak,András Dinnyés,Bob van de Water	16
6	Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays 2020 ·Clinical Cancer Research ·Peter Bouwman,Ingrid van der Heijden,Hanneke van der Gulden,Roebi de Bruijn,(unknown),Setareh Moghadasi,Lodewyk F.A. Wessels,(unknown),Maaike P.G. Vreeswijk,Jos Jonkers	20
7	Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation 2020 ·Journal of Medical Genetics ·Álvaro N.A. Monteiro,Peter Bouwman,Arne Nedergaard Kousholt,Diana Eccles,Gaël A. Millot,Jean‐Yves Masson,Marjanka K. Schmidt,Shyam K. Sharan,Ralph Scully,Lisa Wiesmüller,Fergus J. Couch,Maaike P.G. Vreeswijk	32
8	Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors 2018 ·Cancer Research ·Marco Barazas,Alessia Gasparini,Yike Huang,Aslι Küçükosmanoğlu,Stefano Annunziato,Peter Bouwman,Wendy Sol,Ariena Kersbergen,Natalie Proost,Renske de Korte‐Grimmerink,Marieke van de Ven,Jos Jonkers,Gerben R. Borst,Sven Rottenberg	36
9	Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells 2017 ·Nature Communications ·Pepijn M. Schoonen,Francien Talens,(unknown),Ewa Gogola,Anne Margriet Heijink,Peter Bouwman,Floris Foijer,Madalena Tarsounas,Sohvi Blatter,Jos Jonkers,Sven Rottenberg,Marcel A.T.M. van Vugt	87
10	Suppression of BRCA1 sensitizes cells to proteasome inhibitors 2014 ·Cell Death and Disease ·Yuan Gu,Peter Bouwman,Dario Greco,Jani Saarela,Bhagwan Yadav,Jos Jonkers,Sergey G. Kuznetsov	19
11	A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants 2013 ·Cancer Discovery ·Peter Bouwman,Hanneke van der Gulden,Ingrid van der Heijden,Rinske Drost,Christiaan Klijn,Pramudita R. Prasetyanti,Mark Pieterse,Ellen Wientjens,Jost Seibler,Frans B.L. Hogervorst,Jos Jonkers	92
12	BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny 2012 ·Genes & Development ·Panagiota A. Sotiropoulou,(unknown),(unknown),Aurélie Candi,Peter Bouwman,Virginie Moers,(unknown),Ana Sofia Rocha,Kiyotoshi Sekiguchi,Jos Jonkers,Cédric Blanpain	30
13	BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance 2011 ·Cancer Cell ·Rinske Drost,Peter Bouwman,Sven Rottenberg,Ute Boon,Eva Schut,Sjoerd Klarenbeek,Christiaan Klijn,Ingrid van der Heijden,Hanneke van der Gulden,Ellen Wientjens,Mark Pieterse,Aurélie Catteau,Peter Green,Ellen Solomon,Joanna R. Morris,Jos Jonkers	197
14	Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression 2011 ·The Journal of Pathology ·Peter Bouwman,Rinske Drost,Christiaan Klijn,Mark Pieterse,Hanneke van der Gulden,Ji‐Ying Song,Károly Szuhai,Jos Jonkers	26
15	A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors 2009 ·Clinical Cancer Research ·Bastiaan Evers,Eva Schut,Eline van der Burg,Tanya M. Braumuller,David A. Egan,Henne Holstege,Pauline Edser,David J. Adams,Richard Wade‐Martins,Peter Bouwman,Jos Jonkers	66
16	Mouse models for BRCA1 associated tumorigenesis: From fundamental insights to preclinical utility 2008 ·Cell Cycle ·Peter Bouwman,Jos Jonkers	17
17	Defective paracrine signalling by TGFβ in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia 2004 ·Development ·Rita L. C. Carvalho,Leon Jonker,Marie‐José Goumans,Jonas Larsson,Peter Bouwman,Stefan Karlsson,Peter ten Dijke,Helen M. Arthur,Christine L. Mummery	127
18	Regulation of the activity of Sp1-related transcription factors 2002 ·Molecular and Cellular Endocrinology ·Peter Bouwman,Sjaak Philipsen	394
19	Complex phenotype of mice homozygous for a null mutation in the Sp4 transcription factor gene 2001 ·Genes to Cells ·(unknown),Peter Bouwman,(unknown),Alar Karis,Harald Braun,(unknown),Adriana del Rey,(unknown),Andreas Meinhardt,(unknown),Tyler Cutforth,Frank Grosveld,Sjaak Philipsen,Guntram Suske	50
20	Translation start site multiplicity of the CCAAT/enhancer binding protein α mRNA is dictated by a small 5′ open reading frame 1994 ·Nucleic Acids Research ·Cornelis F. Calkhoven,Peter Bouwman,(unknown),Geert AB	78

About Peter Bouwman

Peter Bouwman is a scholar working on Aging, Genetics and Molecular Biology, having authored 42 papers that have together received 3.4k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (15 papers), BRCA gene mutations in cancer (11 papers) and CRISPR and Genetic Engineering (10 papers). The work is most often cited by research in Oncology (1.1k citations), Molecular Biology (2.5k citations) and Cancer Research (400 citations). Peter Bouwman has collaborated with scholars based in Netherlands, United Kingdom and United States. Frequent co-authors include Jos Jonkers, Sjaak Philipsen, Christine L. Mummery, Sven Rottenberg, Jean‐Philippe Pradère, Catelijne Stortelers, Paula Ruurs, Marga A. van Rooijen, Wouter H. Moolenaar and Michael J.O. Wakelam. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact